Open Calls for Input and Feedback


Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.

At CADTH, input is information, insight, or advice given to CADTH to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.

Draft Recommendations

lurbinectedin (Zepzelca)

Therapeutic Area: metastatic small cell lung cancer (SCLC)
Draft recommendations posted for stakeholder feedback: August 4, 2022
End of feedback period: August 18, 2022
Draft Recommendation

Submit Feedback

 

atezolizumab (Tecentriq)

Therapeutic Area: Non-small cell lung cancer
Draft recommendations posted for stakeholder feedback: August 4, 2022
End of feedback period: August 18, 2022
Draft Recommendation

Submit Feedback

 

atezolizumab (Tecentriq)

Therapeutic Area: Small Cell Lung Cancer
Draft recommendations posted for stakeholder feedback: August 4, 2022
End of feedback period: August 18, 2022
Draft Recommendation

Submit Feedback

 

pembrolizumab (Keytruda)

Therapeutic Area: Triple-negative breast cancer
Draft recommendations posted for stakeholder feedback: August 4, 2022
End of feedback period: August 18, 2022
Draft Recommendation

Submit Feedback

 

pembrolizumab and lenvatinib (Keytruda and Lenvima)

Therapeutic Area: Advanced endometrial cancer
Draft recommendations posted for stakeholder feedback: August 4, 2022
End of feedback period: August 18, 2022
Draft Recommendation

Submit Feedback

 

Open Calls for Patient and Clinician Input

Therapeutic Area
Therapeutic Area: Acute lymphoblastic leukemia
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Iron deficiency anemia
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Chronic kidney disease
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Paroxysmal nocturnal hemoglobinuria
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: KRAS G12C-mutated advanced NSCLC
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Acute lymphoblastic leukemia
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Venous thromboembolic events (VTE)
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Diabetes mellitus, type 2
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Metastatic castration sensitive prostate cancer (mCSPC).
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed:
Therapeutic Area
Therapeutic Area: Osteoporosis, postmenopausal women
Call For Patient Input:
Call For Patient Input:
Patient Input Closed
Patient Input Closed: